What the FDA labels say about taking them together
Gemfibrozil and pravastatin
Gemfibrozil's FDA label of April 10, 2026 names pravastatin in its drug interactions section, and pravastatin's label names gemfibrozil too. The pravastatin label: “There is an increased risk of myopathy/rhabdomyolysis when pravastatin is administered with gemfibrozil”
Check it at the source: the gemfibrozil FDA label on DailyMed (effective April 10, 2026, Northstar RxLLC); the pravastatin FDA label on DailyMed (effective July 31, 2026, Apotex Corp.).
What does the gemfibrozil label say about pravastatin?
Gemfibrozil label, drug interactions(D) OATP1B1 substrates: Gemfibrozil is an inhibitor of OATP1B1 transporter and may increase exposure of drugs that are substrates of OATP1B1 (e.g., atrasentan, atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, SN-38 [active metabolite of irinotecan], rosuvastatin, pitavastatin, pravastatin, rifampin, valsartan, olmesartan).
Source: FDA drug label (Gemfibrozil), Northstar RxLLC, effective April 10, 2026 (SPL set 75cac02c-56e3-4dfe-b1e2-4ce166b28833), via openFDA; the full label on DailyMed
What does the pravastatin label say about gemfibrozil?
Pravastatin label, drug interactionsGemfibrozil Clinical Impact: There is an increased risk of myopathy/rhabdomyolysis when pravastatin is administered with gemfibrozil Intervention: Avoid concomitant use of gemfibrozil with pravastatin.
Pravastatin label, warnings and precautionsSteps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis Pravastatin is not recommended in patients taking gemfibrozil [see Drug Interactions ( 7 )].
Source: FDA drug label (PRAVASTATIN SODIUM), Apotex Corp., effective July 31, 2026 (SPL set dcf45e4f-b46e-6fbb-b67a-2ff619ab1780), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Gemfibrozil | Pravastatin | |
|---|---|---|
| Labeled for | High cholesterol, Heart attack and coronary artery disease | Heart attack and coronary artery disease, High cholesterol, High triglycerides |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.104 per tablet 600 mg tablet | $0.058 per tablet 20 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once